(Diphenylphosphino)alkyl-Functionalized Nucleophilic Carbene Complexes of Palladium

Nikolaos Tsoureas,[†] Andreas A. Danopoulos,^{*,†} Arran A. D. Tulloch,[‡] and Mark E. Light[†]

> Department of Chemistry, University of Southampton, Highfield, Southampton, U.K. SO17 1BJ, and Johnson Matthey Catalysts, Belasis Avenue, Billingham, Cleveland, U.K. TS23 1LB

> > Received July 22, 2003

The (diphenylphosphino)alkyl-functionalized nucleophilic heterocyclic carbene (NHC) complexes of palladium LPdX₂ (L = $(3-R^1)[1-Ph_2P(CH_2)_2]$ -imidazol-2-ylidene; R¹ = 2,6-Prⁱ₂C₆H₃, 2,4,6-Me₃C₆H₂; X = CH₃ (**3a,b**), X = Br (**4a,b**)) have been synthesized by the reaction of the in situ generated functionalized NHC ligand L^a or L^b with Pd(tmed)(CH₃)₂ and Pd(COD)Br₂, respectively, and structurally characterized. Interaction of **3a** with H(Et₂O)-{B[3,5-(CF₃)₂C₆H₂]₄} and pyridine or with (CF₃)₂CHOH and pyridine in CH₂Cl₂ gave the monocationic complexes [(L^a)Pd(CH₃)(pyridine)]⁺(A)⁻ (A⁻ = {B[(3,5-CF₃)₂C₆H₂)]₄⁻, (CF₃)₂CHO⁻); acetonitrile and benzonitrile analogues can be prepared in an analogous way. Reaction of **4a** with AgBF₄ in MeCN gave the dicationic complexes [(L^a)Pd(MeCN)₂](BF₄)₂. Complexes **3** show moderate catalytic activity for the coupling of acrylates with aryl bromides but not chlorides. The cationic species generated in situ from **3a** and H(Et₂O){B[(3,5-CF₃)₂C₆H₂)]₄} in CH₂Cl₂ under CO/ethylene acts as a copolymerization catalyst under mild conditions.

Introduction

There is a continuing effort to improve our mechanistic understanding of the organometallic transformations and catalytic reactions involving NHC complexes.¹ The reductive elimination of methylimidazolium salts from $[Pd(tmim)CH_3(L)_2]^+$ (tmim = tetramethylmethylimidazol-2-ylidene, L = phosphine, phosphite) and the microscopic reverse, oxidative addition, have been observed in simple systems and studied by theoretical methods;² methyl migration to the NHC carbon has also been observed in a Pd complex with a preorganized "pincer" NHC ligand and studied theoretically.³ The extent of these reactions is critically dependent on the nature of the coligating functionalities, the presence and size of chelating rings, and other structural variables. Consequently, the design of successful carbene catalysts should be based on ligands promoting productive catalytic steps while inhibiting decomposition or deactivation. The use of bulky groups on imidazole and imidazolin-2-ylidene is becoming a common feature of most catalytically active complexes. In addition, incorporation of the carbene functionality into ligand systems containing other "classical" donor groups facilitates electronic tuning of the metal coordination sphere.⁴

We have recently reported the synthesis of several thermally stable N-functionalized NHCs with various substituted pyridines, ethers, and arylphosphines.⁵ Furthermore, a range of complexes with platinum-group metals, mainly Pd, Ru, Ir, and Rh, have been also prepared by the interaction of the isolated or in situ generated functionalized NHCs or their silver adducts with transition-metal precursors.⁶ Herein, we wish to report the synthesis, structural characterization, and selected reactions of 3-aryl-1-(β -(diphenylphosphino)ethyl)imidazol-2-ylidene (aryl = 2,6-Prⁱ₂-C₆H₃, L^a; aryl = 2,4,6-trimethylphenyl, L^b) complexes of palladium. The compounds described in the paper are summarized in Scheme 1.

Results and Discussion

Ligand Synthesis. The ligand synthetic strategy is shown in Scheme 2.

It is based on the quaternization of 1-arylimidazoles with (ω -bromoalkyl)diphenylphosphine oxide followed by reduction with SiHCl₃. A similar procedure was used for the synthesis of the 1-(β -(diphenylphosphino)ethyl)-3-methylimidazolium salt.⁴ However, under the previously reported conditions both reaction steps failed with the bulky, less nucleophilic 1-arylimidazoles. When the

^{*} To whom correspondence should be addressed. E-mail: ad1@ soton.ac.uk.

[†] University of Southampton.

[‡] Johnson Matthey Catalysts.

⁽¹⁾ For recent reviews of the area see: (a) Herrmann, W. A. Angew. Chem., Int. Ed. **2002**, 41, 1290. (b) Bourisou, D.; Guerret, O.; Gabbai, F. P.; Bertrand, G. Chem. Rev. **2000**, 100, 39.

Chem., Int. Ed. 2002, 41, 1250. (b) Bourison, D., Guerrer, O., Gabbal,
 F. P.; Bertrand, G. Chem. Rev. 2000, 100, 39.
 (2) (a) McGuinness, S.; Saendig, N.; Yates, B. F.; Cavell, K. J. J.
 Am. Chem. Soc. 2001, 123, 4029. (b) McGuiness, S.; Cavell, K. J.; Yates,
 B. F.; Skelton, B. W.; White, A. H. J. Am. Chem. Soc. 2001, 123, 8317.
 (c) Gründemann, S.; Albrecht, M.; Kovacevic, A.; Faller, J. W.; Crabtree,
 R. H. J. Chem. Soc., Dalton Trans. 2002, 2163.


⁽³⁾ Danopoulos, A. A.; Tsoureas, N.; Green, J. C.; Hursthouse, M. B. *Chem. Commun.* **2003**, 756.

⁽⁴⁾ Herrmann, W. A.; Köcher, C.; Goossen, L. J.; Artus, G. R. J. Chem. Eur. J. **1996**, 2, 1627.

⁽⁵⁾ Danopoulos, A. A.; Gelbrich, T.; Hursthouse, M. B.; Winston, S. *Chem. Commun.* **2002**, 482.


<sup>Chem. Commun. 2002, 482.
(6) (a) Danopoulos, A. A.; Tulloch, A. A. D.; Winston, S.; Hursthouse, M. B.; Eastham, G. Dalton Trans. 2003, 699 and references therein.
(b) Danopoulos, A. A.; Tulloch, A. A. D.; Winston, S.; Hursthouse, M. B.; Eastham, G. Dalton Trans. 2003, 1009. (c) Lappert, M. F. J. Organomet. Chem. 1993, 451, 389. (d) Arnold, P. L.; Scarisbrick, A. C.; Blake, A. J.; Wilson, C. Chem. Commun. 2001, 2340. (e) Fürstner, A.; Krause, H.; Ackermann, L.; Lehmann, C. W. Chem. Commun. 2001, 2240.</sup>

Scheme 1. Palladium Complexes and Chemical Transformations Described in This Paper^a



^{*a*} Compound given in boldface type have been structurally characterized. Reagents and conditions: (i) 1.1 equiv of KN(SiMe₃)₂, THF, -78 °C and then 1 equiv of tmedPd(CH₃)₂; (ii) 1.1 equiv of KN(SiMe₃)₂, THF, -78 °C and then 1 equiv of (1,5-COD)PdCl₂; (iii) CH₃I excess in THF; (iv) 1 equiv of H(Et₂O){B[(3,5-CF₃)₂C₆H₂)]₄} at -78 to -30 °C and then 1 equiv of Py; (v) 1 equiv of H(Et₂O){B[(3,5-CF₃)₂C₆H₂)]₄} at -78 to -30 °C and then 1 equiv of H(Et₂O){B[(3,5-CF₃)₂C₆H₂)]₄} at -78 to -30 °C and then 1 equiv of PMe₃; (vii) 2 equiv of AgBF₄ in CH₃CN.

Scheme 2. Synthesis of the Ligand Precursor Imidazolium Salts^a



^{*a*} Reagents and conditions: (i) $Ph_2P(=O)(CH_2)_nBr$, 150–160 °C, 4–5 days; (ii) SiHCl₃ in chlorobenzene, 120 °C (n = 2, 3).

quaternization reactions were carried out at 150–160 °C (most conveniently in the melt in the absence of solvent), they gave good yields. Furthermore, the yield of the subsequent reduction was also dramatically improved when using SiHCl₃ in refluxing chlorobenzene as a reducing agent. The synthesis of the 1-(β -(diphenylphosphino)ethyl)-3-mesitylimidazolium salt (L^bH)Br from 1-(β-bromoethyl)-3-mesitylimidazolium and PPh₂H in DMSO in the presence of KOBut has recently been communicated, although the reported yields were poor.⁷ All imidazolium phosphines were isolated as white, airsensitive powders and characterized by spectroscopic and analytical methods. The microanalysis data support the presence of mixed chloride/bromide salts; the chloride ion originates from the hydrolytic workup of the excess SiHCl₃ during the reduction step. Mixed halide imidazolium salts and palladium NHC complexes have been observed before.^{6a}

Synthesis of the Palladium Complexes. Neutral **Species.** The best method for the introduction of the new functionalized NHC ligands onto the palladium center is by trapping of the in situ generated L with a suitable metal precursor. The generation of carbenes by deprotonation of the imidazolium precursors with KN(SiMe₃)₂ in THF is complete within a few minutes at -78 °C. Reaction of L with Pd(tmed)(CH₃)₂ or Pd(1,5-COD)Br₂ gave good yields of complexes 3 and 4. The isolation and characterization of the free L^a has already been communicated,⁵ and details on its reactivity together with other N-functionalized NHCs will be reported in a forthcoming paper. The air-stable, colorless 3a,b are soluble in THF and CH₂Cl₂, although the two solutions in the latter develop a dark coloration on standing at room temperature for 2-3 h. Complexes 4a,b are yellow and soluble in THF and CH₂Cl₂ but insoluble in CHCl₃. They were characterized by spectroscopic and analytical methods.

The observed ¹H NMR spectra of the new complexes are consistent with nonsymmetric structures. The doublets at δ –0.4 to –0.6 in the spectra of **3** are attributable to inequivalent Pd–CH₃ groups. They are almost isochronous with the methyls of Pd(tmed)(CH₃)₂⁸ but more shielded relative to the methyls of *cis*-Pd(P)₂(CH₃)₂ (P = tertiary phosphine)⁹ and the recently reported *cis*-Pd(CH₃)₂[(carbene-CH₂)₂].¹⁰ The ethylene bridge protons appear as two sets of multiplets. In **3a** the *o*-isopropyl methyls are diastereotopic and appear as two doublets. Characteristic signals for the carbene carbons are

⁽⁸⁾ de Graaf, W.; Boersma, J.; Smeets, W. J. J.; Spek, A. L.; van Koten, G. *Organometallics* **1989**, *8*, 2907.

 ⁽⁹⁾ Tooze, R.; Chiu, K. W.; Wilkinson, G. *Polyhedron* 1984, *3*, 1025.
 (10) Douthwaite, R. E.; Green, M. L. H.; Silcock, P. J.; Gomes, P. T. *J. Chem. Soc., Dalton Trans.* 2002, 1386.




Figure 1. ORTEP representation of the structure of **3a** showing 50% probability ellipsoids. H atoms are omitted for clarity. Selected bond lengths (Å) and angles (deg) with estimated standard deviations: C(1)-N(1) = 1.357(6), C(1)-N(2) = 1.389(6), C(1)-Pd(1) = 2.088(5), P(1)-Pd(1) = 2.2994(13), C(30)-Pd(1) = 2.098(5), C(31)-Pd(1) = 2.111(5); N(1)-C(1)-Pd(1) = 124.4(4), N(2)-C(1)-Pd(1) = 131.6(4), C(1)-Pd(1)-P(1) = 91.06(14), C(30)-Pd(1)-P(1) = 89.23(15), C(31)-Pd(1)-P(1) = 172.31(14), C(1)-Pd(1)-C(31) = 95.84(18), C(1)-Pd(1)-C(30) = 177.0(2), C(30)-Pd(1)-C(31) = 84.05(19).

observed as singlets in the range δ 185–187 for 3 and δ 160–165 for 4.

X-ray-quality crystals of **3a** were obtained by layering a THF solution with ether. The structure of **3a** as determined by single-crystal X-ray diffraction is shown in Figure 1. The geometry around the palladium is square planar, and the ligand acts as a chelate occupying two cis positions. The two Pd–CH₃ bond lengths, 2.098(5) and 2.111(5) Å, are equal within the esds. The Pd–C(carbene) bond length at 2.088(5) Å is comparable to that recently reported, where the NHC is trans to an alkyl group.¹⁰ The six-membered chelate ring is puckered, and the ligand bite angle is 91.06(14)°.

It is interesting to note that, due to the fact that the NHC ligands are better σ -donors than trialkylphosphines, they should be exerting a higher trans influence, which is not evidenced by the structural data of **3a**. However, the reactivity reported below shows that the two cis methyls are kinetically different.

X-ray-quality crystals of **4b** have been obtained by slow diffusion of ether in CH_2Cl_2 solution of the complex. The structure of the molecule, as determined by singlecrystal X-ray diffraction, is shown in Figure 2. The geometry around the metal is square planar, with the ligand occupying two cis sites. The Pd–Br bond trans to the P atom is longer than that trans to the NHC by ca. 0.03 Å. This observation is in contrast to that expected on the basis of the relative trans influence of the phosphine and NHC ligands and is not understood at present. The Pd–carbene bond length is the same as that observed in **3a** within the observed esds. Finally, the Pd–P bond length in **3a** is longer in **4b**, as expected.

The existence of two types of Pd–C bonds (i.e. Pd– CH₃ and Pd–carbene) in **3a**, arranged in a way that one Pd–CH₃ bond is flanked by one Pd–CH₃ bond and one Pd–carbene bond, provides an opportunity to test the preferred decomposition pathway of the complexes by reductive elimination of either ethane or methylimidazolium. Complexes **3** are stable at room temperature in the solid state or in solution. Heating a d_8 -THF solution of **3a** to 60 °C results in the formation of




Figure 2. ORTEP representation of the structure of **4b** showing 50% probability ellipsoids. H atoms are omitted for clarity. Selected bond lengths (Å) and angles (deg) with estimated standard deviations: C(1)-Pd(1) = 1.996(3), P(1)-Pd(1) = 2.2461(7), Pd(1)-Br(1) = 2.4989(3), Pd(1)-Br(2) = 2.4708(3), C(1)-N(1) = 1.349(3), C(1)-N(2) = 1.349(3); N(1)-C(1)-Pd(1) = 129.9(9), N(2)-C(1)-Pd(1) = 124.8(2), C(1)-Pd(1)-Br(2) = 176.63(7), C(1)-Pd(1)-P(1) = 89.24(8), C(1)-Pd(1)-Br(1) = 90.37(7), P(1)-Pd(1)-Br(1) = 168.96(2), P(1)-Pd(1)-Br(2) = 89.32(2), Br(2)-Pd(1)-Br(1) = 91.622(11).

palladium colloids and a colorless solid. The NMR spectrum shows only the existence of **3a** in solution, while formation of ethane or methane was not observed. Removal of the volatiles, extraction in dichloromethane, and filtration through Celite resulted in a beige-yellow solution. The ES+ mass spectrum of this solution in acetonitrile showed the presence of 2-methyl-[3-(2,6-diisopropylphenyl)-1-(β -((diphenylphosphino)oxy)ethyl)]-imidazolium as well as the cationic [(L^a)PdMe]⁺ and [(L^a)PdMe+MeCN]⁺ in a 1:1 ratio.

Attempts were also made to explore the reactivity of **3a** with CH_3I . It is established that $Pd(L-L)(CH_3)_2$ (L-L = tmed, bipy, phen) react with CH_3I to form Pd(IV) complexes. Some of them have been characterized structurally.^{8,11} The Pd(IV) methyls can reductively eliminate ethane and form new Pd(II) complexes. Reaction of 3a with excess CH₃I in CH₂Cl₂ at room temperature gave after crystallization from dichloromethane/ ether the product **5a**. Its identity was unequivocally established by single-crystal X-ray diffraction and is shown in Figure 3. The molecule comprises a squareplanar Pd center coordinated by one imidazolium-functionalized phosphine, two iodides, and one chloride. The bond lengths and angles are not unusual. We believe that the source of chloride is chlorinated solvent. A plausible mechanism for the formation of **5a** is given in Scheme 3. It involves successive Pd(II)-Pd(IV) oxidative addition of CH₃I and reductive elimination of CH₃CH₃ leading to L^aPdI₂. The last oxidative addition is followed by reductive elimination of methylimidazolium cation, leading to the observed species. Reductive elimination of methylimidazolium after the first oxidative addition step is also plausible, leading to iodo dimethyl species, which can undergo further oxidative addition steps to the observed product. An alternative pathway involving Pd(II)-Pd(0) cycles is less likely, on the basis of the high thermal stability of **3a** at room temperature. Attempts to monitor the reaction by VT NMR spectroscopy (¹H and ${}^{31}P{}^{1}H$) showed that the formation of methylimidazolium (singlet at 2.4 ppm) occurs at room tempera-

(11) Canty, A. J. Acc. Chem. Res. 1992, 25, 83.






Figure 3. ORTEP representation of the structure of the cation in **5a** showing 50% probability ellipsoids. H atoms are omitted for clarity. Selected bond lengths (Å) and angles (deg) with estimated standard deviations: Pd(1)-I(1) = 2.6613(7), Pd(1)-P(4) = 2.2483(18), Pd(1)-I(2) = 2.6674-(7), C(1)-C(4) = 1.470(10), C(1)-C(4) = 1.470(10), Pd(1)-I(3) = 2.360(5), C(1)-N(1) = 1.353(9), C(2)-C(3) = 1.335-(10), C(1)-N(2) = 1.335(9); I(3)-Pd(1)-I(1) = 168.10(14), I(1)-Pd(1)-I(2) = 92.25(2), I(3)-Pd(1)-I(2) = 86.37(11), P(4)-Pd(1)-I(1) = 90.98(5), P(4)-Pd(1)-I(3) = 90.07(12).





ture overnight and is accompanied by disappearance of the two Pd - Me doublets and the formation of ethane. However, a complex reaction mixture prevented the full identification of all products from the reaction.

Cationic Species. Square-planar cationic complexes of palladium and nickel stabilized by bidentate chelating ligands have received much attention, due to their involvement in catalytic C–C bond-forming reactions.^{10,12} The most studied ligands include diphosphines and diimines, although in recently published reports cationic complexes with chelating dicarbenes¹⁰ have been observed spectroscopically and in some cases structurally characterized.¹³ Furthermore, mixed donor nonsymmetric chelating neutral or anionic ligands with N–O, P–P', P–N, and P–O donor atoms have also been studied.¹⁴ We thought that the mixed donor chelates L^a and L^b synthesized in this paper could give rise to the first cations incorporating chelates with nonsymmetric NHC and "classical" donors and provide useful insight into the mechanism of their formation and possible catalytic activity.

Recent reports^{2a} provide experimental and theoretical evidence that cationic *cis*-[L₂Pd(NHC)(CH₃)]⁺ complexes undergo facile concerted reductive elimination, resulting in the formation of alkylimidazolium salts. However, chelating ligands (i.e. $L_2 = dppp$) suppress this transformation.^{2a} The results presented below amplify the fact that Pd(II) cationic complexes with NHC donors as part of a chelate ring are resistant to reductive elimination of alkylimidazolium salts and show that cation formation occurs with unexpected regiospecificity.

The interaction of **3a** with 1 equiv of $(CF_3)_2$ CHOH in CH_2Cl_2 or CH_2Cl_2 /ether at -78 °C and warming to -20°C results in the formation of Pd black and unidentified decomposition products. However, addition to the above reaction mixture of 1 equiv of pyridine at -30 °C, warming to room temperature, and workup gave a white, air-stable solid. The ¹H NMR spectrum of this solid shows the presence of one methyl attached to the Pd (doublet at δ –0.3), in addition to pyridine and resonances assignable to the L^{a} and the anion [(CF₃)₂CHO⁻]. The appearance of one single Pd-CH₃ peak and one signal in the ³¹P NMR spectrum implies the presence of one isomer in solution. An identical spectrum was obtained by replacing $(CF_3)_2$ CHOH with H(Et₂O){B[(3,5- $(CF_3)_2C_6H_3$, in which case **6a** was isolated and crystallized by slow evaporation of the ether solution. Its structure in the solid state was determined by a single-crystal X-ray diffraction study. A diagram of the molecule is shown in Figure 4.

The geometry around the Pd center in the cation is square planar; its coordination sphere comprises the ligand L^a , one methyl group, and one pyridine ligand. The methyl group is trans to the NHC functionality. The Pd–carbene and Pd–CH₃ bond lengths and ligand bite angle compare with the corresponding values observed in **3a**.

Monitoring the reaction of **3a** with $(CF_3)_2$ CHOH by ¹H NMR spectroscopy provides evidence that the only one isomer is formed under kinetic control and, and this is the isomer characterized crystallographically. The reason for the selective abstraction of the palladium methyl group trans to the phosphorus, in the absence of any apparent trans influence as established by the crystal structure of **3a**, could lie in the different steric demands of the two electronically dissimilar parts of **L**^a. The steric bulk imposed by the phosphine end could hinder the coordination of a donor ligand, thus making the attack to the methyl trans to it more kinetically favored.

Complex **6a** is stable in the solid state and in solution. On prolonged standing at room temperature, it develops a yellow coloration, even though the compound is unchanged spectroscopically. Its stability could possibly

⁽¹²⁾ For a recent review on late-transition-metal cationic complexes as alkene polymerization catalysts see: Ittel, S. D.; Johnson, L. K.; Brookhart, M. *Chem. Rev.* **2000**, *100*, *1169*.

⁽¹³⁾ Gardiner, M. A.; Herrmann, W. A.; Reisinger, C.-P.; Schwarz, J.; Spiegler, M. *J. Organomet. Chem.* **1999**, *572*, 239.

⁽¹⁴⁾ For recent work in this area see: Liu, W.; Malinowski, J. M.; Brookhart, M. Organometallics **2002**, *21*, 2836 and references therein.




Figure 4. ORTEP representation of the structure of the cation in **6a** showing 50% probability ellipsoids. The asymmetric unit consists of two cations and two anions and two molecules of ether. The BAr^f₄ anion, the ether molecules, and the H atoms are omitted for clarity. Selected bond lengths (Å) and angles (deg) with estimated standard deviations: C(36)-Pd(1) = 2.092(6), C(36)-N(4) = 1.356-(6), C(65)-Pd(1) = 2.099(6), N(6)-Pd(1) = 2.128(5), C(36)-N(5) = 1.375(6), P(1)-Pd(1) = 2.2221(18); N(5)-C(36)-Pd(1) = 129.0(4), N(6)-Pd(1)-P(1) = 171.75(13), C(36)-Pd(1)-P(1) = 89.86(17), C(36)-Pd(1)-C(65) = 173.9(2), C(65)-Pd(1)-P(1) = 89.12(17), N(4)-C(36)-Pd(1) = 125.7-(4), C(65)-Pd(1)-N(6) = 84.13(17).

arise from the trans arrangement of the methyl and the NHC groups, rendering methyl migration to the NHC carbon or reductive elimination of methylimidazolium salts unfavorable. Thermal decomposition of **6a** occurs at 90 °C to colloidal Pd and intractable mixtures of organic products (by ¹H NMR).

Complexes 7a, 8a, and 9a were prepared in a way analogous to 6a using acetonitrile, benzonitrile, and trimethylphosphine instead of pyridine, respectively. All three complexes are colorless, air-stable solids. The ¹H NMR spectra show that in these cations as well, the methyl groups are located trans to the NHC. There is no evidence of the presence of any other isomers in solution. This was further established by a single-crystal X-ray diffraction study of 7a. A diagram of the molecule is shown in Figure 5. Here, too, the Pd center in the cation is square planar with chelating L^{a} , one methyl group trans to the NHC end, and one acetonitrile ligand trans to the phosphine. The Pd-carbene and Pd-CH₃ bond lengths and ligand bite angle compare with those observed in **6a**. Complex **7a** is stable in d_3 -acetonitrile up to 65 °C; the only process that can be detected involves exchange of coordinated and free acetonitrile.

Dications are also accessible by the reaction of **4** with AgBF₄ in MeCN. Due to their air and light sensitivity




Figure 5. ORTEP representation of the structure of the cation in **7a** showing 50% probability ellipsoids. The BAr^f₄ anion and H atoms are omitted for clarity. Selected bond lengths (Å) and angles (deg) with estimated standard deviations: C(1)-Pd(01) = 2.090(4), C(6)-Pd(01) = 2.070-(4), N(3)-Pd(01) = 2.091(3), P(1)-Pd(01) = 2.2043(9), C(1)-N(1) = 1.369(4), C(1)-N(2) = 1.358(4), C(7)-N(3) = 1.139(5), C(7)-C(8) = 1.464(5); C(1)-Pd(01)-C(6) = 85.68-(14), C(1)-Pd(01)-P(1) = 93.56(9), P(1)-Pd(01)-N(3) = 169.48(9), N(3)-C(7)-C(8) = 179.4(4), P(1)-Pd(01)-C(6) = 84.32(11), N(2)-C(1)-N(1) = 103.1(3).

and reduced thermal stability complex **9a** was characterized by multinuclear NMR spectroscopy, which supports the structure proposed in Scheme 1. Attempts to crystallize this complex were unsuccessful.

Catalytic Studies. Heck Coupling Reactions. It has been claimed that the imidazolium salts **L**^b**H** in the presence of Pd(dba)₂ and KOBu^t or Cs₂CO₃ are highly active catalysts for the Heck coupling of arylbromides with acrylates.⁷ Our studies using **3a,b** and **4b** as catalysts are given in Table 1. All data given in Table 1 are the average of at least two runs. From the information given, it is clear that **3a,b** show good activity, albeit not as high as previously claimed for catalysts formed in situ. In addition, after the completion of the reaction the formation of Pd colloids was evident in the reaction mixture. Attempts to reproduce the activity reported in the literature under identical conditions met also with limited success in our hands.

Copolymerization of Ethylene and CO. A dichloromethane solution of complex **3a** when pressurized at 5 bar with a mixture of CO and ethylene (1:1) at room temperature, in the presence of Brookhart's acid, yielded the desired copolymer over a period of 2 h.

Conclusions

The high-yield synthesis of chelate (diphenylphosphino)ethyl carbene complexes of palladium(II) established

 Table 1. Representative Catalytic Data for the Heck Coupling of Aryl Halides with Methyl Acrylate in the

 Presence of the Palladium Complexes Reported in This Paper

aryl halide	base	solvent	time (h)	temp (°C)	catalyst loading (M)	yield (%)	TON
p-C(O)MePhBr	NEt ₃	NMP	6	120	$2 imes 10^{-4}$ (3a)	92	184
PhBr	Cs_2CO_3	DMAC	6	120	$2.5 imes10^{-4}$ (3a)	60	122
<i>p</i> -C(O)MePhBr	NEt ₃	NMP	6	120	$2.5 imes10^{-4}$ (3b)	66	134
p-C(O)MePhBr	Cs_2CO_3	NMP	6	120	$2.5 imes10^{-4}$ (3b)	54	110
PhBr ^a	NEt ₃	NMP	12	140	$5 imes 10^{-5}$ (3b)	19	1920
PhBr	NEt ₃	NMP	6	120	2.5×10^{-4} (3b)	22	44
\mathbf{PhBr}^{c}	NEt ₃	NMP	12	140	5×10^{-5} (3b)	22	2242
\mathbf{PhBr}^{b}	NEt ₃	NMP	6	120	$2.5 imes 10^{-4}$ (3b)	14	28

^{*a*} Alkene is *n*-butyl acrylate; 2 mL of [2.2.1]-1,5-norbonadiene was added. ^{*b*} In the presence of 1.1 equiv of N₂H₄·H₂O. ^{*c*} Alkene is *n*-butyl acrylate.

a new family of well-defined, electronically nonsymmetric, square-planar complexes. The thermally stable dimethyl analogues served as useful starting materials for the synthesis of cationic species by their reaction with Lewis acids containing noncoordinating anions. In all studied cases only one cationic isomer in which the methyl is trans to the carbene is spectroscopically observed and isolated. The reasons for this selectivity are not well understood.

Furthermore, the neutral dimethyl complexes showed moderate catalytic activity in the Heck coupling of aryl halides with acrylates. This activity is lower than that previously reported for systems generated in situ from Pd(dba)₂ and the (diphenylphosphino)ethyl imidazolium salts in the presence of Cs_2CO_3 . The synthesis of well-defined chelate (diphenylphosphino)ethyl carbene Pd(0) complexes, which is under way, may provide an explanation for the reduced catalytic activity observed with the Pd(II) complexes.

Experimental Section

General Methods. Elemental analyses were carried out by the University College, London, microanalytical laboratory. All manipulations were performed under nitrogen in a Braun glovebox or using standard Schlenk techniques, unless stated otherwise. Solvents were dried using standard methods and distilled under nitrogen prior to use. The light petroleum used throughout had a boiling point of 40-60 °C.

The starting materials 1-(2,6-diisopropylphenyl)imidazole, 1-(2,4,6-trimethylphenyl)imidazole,¹⁵ Ph₂POEt,¹⁶ Ph₂P(O)-(CH₂)₂Br,¹⁶ Pd(tmed)Me₂,⁸ and Pd(COD)Br₂¹⁷ were prepared according to literature procedures. Ph₂P(O)(CH₂)₃Br was prepared from Ph₂POEt and 1,3-C₃H₆Br₂ by a method analogous to that for Ph₂P(O)(CH₂)₂Br and was recrystallized from benzene/petroleum. NMR data were recorded on Bruker AMX-300 and DPX-400 spectrometers, operating at 300 and 400 MHz (1H), respectively. The spectra were referenced internally using the signal from the residual protio solvent (¹H) or the signals of the solvent (13C). 31P{1H} spectra were recorded on a Bruker AC-300 spectrometer at 121.44 MHz and referenced externally relative to 85% H₃PO₄ in D₂O. ¹⁹F spectra were recorded on a Bruker AC-300 instrument at 282.36 MHz and were referenced externally relative to C₆F₆. The phosphine oxide-imidazolium salts are hygroscopic, while the ligand precursors **2a**-**c** are mixtures of the bromide and chloride salts.

3-(2,6-Diisopropylphenyl)-1-(β -((diphenylphosphino)oxy)ethyl)imidazolium Bromide (1a). A 9.7 g (31.5 mmol) portion of Ph₂P(O)(CH₂)₂Br and 7.2 g (31.6 mmol) of (2,6diisopropylphenyl)imidazole were placed in a glass ampule, which was then sealed under vacuum and immersed in an oil bath heated at 150-160 °C for 1 week. After the ampule was opened, the brown solid was dissolved in dichloromethane and the volatiles were removed under reduced pressure to yield a beige solid, which was washed with ether (2 \times 50 mL). It was then redissolved in the minimum amount of dichloromethane and reprecipitated by addition of ether, giving the product as a white powder. Yield: 15.2 g (90%). NMR (CDCl₃): ¹H, δ 0.9 $(d, {}^{3}J_{HH} = 6.9 \text{ Hz}, 6H, CH(CH_{3})_{2}), 1.1 (d, {}^{3}J_{HH} = 6.9 \text{ Hz}, 6H,$ $CH(CH_3)_2$), 2.1 (septet, 2H, ${}^3J_{HH} = 6.9$ Hz, $CH(CH_3)_2$), 3.4 (2H, m, Ph₂P(O)CH₂CH₂-imidazole), 5.1 (m, 2H, Ph₂P(O)CH₂CH₂imidazole), 6.9 (s, 1H, imidazole backbone), 7.1-7.2 (m, 3H, aromatics and the other imidazole backbone), 7.4-7.7 (m, 8.5H, aromatics), 7.8-8.0 (m, 4.5H, aromatics), 8.7 (s, 1H,

aromatic), 10.3 (s, 1H, NC(H)N proton); ${}^{13}C{}^{1}H$, δ 24.41 (s, CH(CH₃)₂), 24.47 (s, CH(CH₃)₂), 28.7 (s, Ph₂P(O)CH₂CH₂imidazole), 44.6 (s, Ph₂P(O)CH₂CH₂-imidazole), 123.9 (s, imidazole backbone), 124.8 (s, aromatic), 125 (s, imidazole backbone), 129.2 (d, J_{PC} = 12.08 Hz, aromatic), 130.2 (s, aromatic), 130.9 (d, $J_{PC} = 9.81$ Hz), 132 (s, aromatic), 132.1 (s, aromatic), 132.5 (s, aromatic), 138.4 (s, ipso at imidazole moiety), 145.4 (s, NCN); ${}^{31}P{}^{1}H$, δ 33.4 ppm (s, Ph₂P(O)-(CH₂)₂-imidazole). Anal. Found: C, 61.93; H, 6.14; N, 5.12. Calcd for C₂₉H₃₄BrN₂OP·H₂O: C, 62.70; H, 6.63; N, 5.04.

3-Mesityl-1-(β-((diphenylphosphino)oxy)ethyl)imidazolium Bromide (1b). This was prepared by a method analogous to 1a from 10 g (32.5 mmol) of Ph₂P(O)(CH₂)₂Br and 6.1 g (32.6 mmol) of mesitylimidazole. Yield: 13.4 g, 83%. NMR (CDCl₃): ¹H, δ 1.8 (s, 6H, *o*-methyls of mesityl), 2.7 (s, 3H, p-methyl of mesityl), 3.4 (m, 2H, Ph₂P(O)CH₂CH₂imidazole), 4.8 (m, 2H, Ph₂P(O)CH₂CH₂-imidazole), 6.6 (s, 1H, imidazole backbone), 6.9 (s, 1H, imidazole backbone), 7.2-7.5 (m, 5H, aromatics), 7.7-7.9 (m, 4H, aromatics), 8.4 (s, 1H, aromatic), 10.1 (s, 1H, NCN proton); ${}^{13}C{}^{1}H$, δ 17.8 (s, o-methyls of mesityl), 21.2 (s, p-methyl of mesityl), 44.5 (s, Ph₂P(O)CH₂CH₂-imidazole), 122.8 (s, imidazole backbone), 124.8 (s, imidazole backbone), 129.1 (d, $J_{\rm PC}$ = 12.83 Hz, aromatic), 129.8 (s, aromatic), 131 (d, $J_{PC} = 18.12$ Hz, aromatic), 131.4 (s, aromatic), 132.2 (s, aromatic), 134.7 (s, aromatic), 138.3 (s, ipso to the imidazole moiety), 141.3 (s, NCN); ${}^{31}P{}^{1}H$, δ 31.0 (s, Ph₂P(O)(CH₂)₂-imidazole). Anal. Found: C, 62.90; H, 5.70; N, 5.64. Calcd for C₂₆H₂₈BrN₂OP: C, 63.04; H, 5.70; N, 5.64.

3-Mesityl-1-(y-((diphenylphosphino)oxy)-n-propyl)imidazolium Bromide (1c). This was prepared by following a method analogous to that for 1a from 4.34 g (13.5 mmol) of Ph₂P(O)(CH₂)₃Br and 2.80 g (15 mmol) of mesitylimidazole. Yield: 6.09 g (89%). NMR (CDCl₃), ¹H, δ 1.9 (s, 6H, *o*-methyls of mesityl), 2,4 (s, 3H, p-methyl of mesityl), 2.3-2.5 (m, 2H, Ph₂P(O)CH₂(CH₂)₂-imidazole), 2.6-2.8 (m, 2H, Ph₂P(O)-CH₂CH₂CH₂-imidazole), 5.0 (t, 2H, Ph₂P(O)(CH₂)₂CH₂-imidazole), 6.9 (s, 2H, aromatics of mesityl), 7.1 (s, 1H, imidazole backbone), 7.3 (s, 1H, imidazole backbone), 7.5 (br s, 5H, aromatics of phosphine oxide), 7.7-7.9 (m, 4H, aromatic), 8.2 (s, 1H, aromatic), 10.4 (s, 1H, NC(H)N proton); 13 C, δ 17.9 (s, o-methyls of mesityl), 21 (s, p-methyl of mesityl), 24.6 (d, 1 J_{PC} = 11.57 Hz, Ph₂P(O)*C*H₂CH₂CH₂-imidazole), 27.0 (s, Ph2PCH2CH2CH2-imidazole), 50.8 (s, Ph2PCH2CH2CH2-imidazole), 122.5 (s, imidazole backbone), 123.9 (s, imidazole backbone), 127.5 (d, $J_{PC} = 6.63$ Hz, aromatic), 128.3 (s, aromatic), 129.1 (s, aromatic), 131.3 (d, $J_{PC} = 17.34$ Hz, aromatic), 131.6 (s, aromatic), 132.9 (s, aromatic), 133.6 (s, aromatic), 138.8 (s, ipso to the imidazole moiety), 142.3 (s, NCN); ³¹P{¹H}, δ 33.8 (s, Ph₂P(O)(CH₂)₃-imidazole).

3-(2,6-Diisopropylphenyl)-1-(β -(diphenylphosphino)ethyl)imidazolium Bromide (2a; L^aH). The phosphine oxide 1a (4.5 g, 8.4 mmol) was placed in a three-neck 1 L flask (Schlenk adapter, double-jacket condenser, and a pressureequalizing funnel) and was dissolved in 110 mL of chlorobenzene by heating to the reflux temperature under a nitrogen atmosphere. The temperature was then maintained at 120 °C (oil bath), and excess trichlorosilane was added in small portions (14 mL, 100.7 mmol, 12-fold excess). After completion of the addition, the reaction mixture was heated at 120 °C for 3 h and then cooled to room temperature. After addition of 100 mL of CH₂Cl₂ the excess of trichlorosilane was quenched by careful dropwise addition of 300 mL of degassed 10% NaOH (aqueous) at 0 °C. The organic phase was separated, and the aqueous phase was washed with CH_2Cl_2 (3 \times 50 mL). After the combined organic extracts were dried over MgSO4, the volatiles were removed under reduced pressure and the resulting white solid was washed with ether (2×150 mL) and dried under vacuum overnight. The imidazolium salt was further dried azeotropically with toluene and was stored in the glovebox. Yield: 3.3 g (75%). NMR (CDCl₃): 1 H, δ 1.1 (d,

^{(15) (}a) Johnson, A. L.; Del, W. U.S. Patent 3,637,731, 1972; Chem.

6H, CH(C*H*₃)₂), 1.2 (d, 6H, CH(C*H*₃)₂), 2.4 (sept, 2H, C*H*(CH₃)₂), 2.9 (m, 2H, PPh₂C*H*₂CH₂-imidazole), 4.9 (m, 2H, PPh₂-CH₂C*H*₂-imidazole), 6.9 (s, 1H, imidazole backbone), 7.1–7.8 (m, 13H, aromatics), 8.0 (s, 1H, aromatic), 10.4 (s, 1H, NCN proton); ¹³C{¹H}, δ 24.5 (s, CH(*C*H₃)₂), 28.8 (s, *C*H(CH₃)₂), 30.0 (d, ¹*J*_{P-C} = 12.98 Hz, PPh₂CH₂CH₂-imidazole), 48.2 (d, ²*J*_{P-C} = 18.12 Hz, PPh₂CH₂CH₂-imidazole), 123.8 (s, imidazole backbone), 124.0 (s, imidazole backbone), 124.8 (s, aromatic), 129.05 (d, *J*_{P-C} = 6.78 Hz, aromatic), 130.3 (s, aromatic), 130.8 (s, aromatic), 132 (s, aromatic), 132.9 (d, *J*_{P-C} = 19.55 Hz, aromatic), 136.2 (d, *J*_{P-C} = 11.32 Hz, aromatic), 138.6 (s, ipso to imidazole moiety, aromatic), 145.5 (s, N*C*N); ³¹P{¹H}, δ -22.4 (s, Ph₂*P*(CH₂)₃-imidazole). Anal. Found: C, 69.07; H, 6.63; N, 5.08. Calcd for C₅₈H₆₈BrClN₄P₂ (1:1 bromide/chloride salt): C, 69.77; H, 6.86; N, 5.61.

3-Mesityl-1-(β-(diphenylphosphino)ethyl)imidazolium Bromide, L^bH (2b). This was prepared by a method analogous to 2a from 5 g (10.1 mmol) of the phosphine oxide and 18 mL of trichlorosilane. Yield: 3.6 g, 75%. NMR (CDCl₃): ¹H, δ 2.1 ppm (s, 6H, o-methyls of mesityl), 2.4 ppm (s, 3H, p-methyl of mesityl), 2.9 (m, 2H, Ph₂PCH₂CH₂imidazole), 4.9 (m, 2H, Ph₂PCH₂CH₂-imidazole), 6.7 (s, 1H, imidazole backbone), 6.9 (s, 1H, imidazole backbone), 7.0 (aromatics of mesityl), 7.5 (5H, br, aromatics), 7.6 (br, 4H, aromatic), 7.9 (s, 1H, aromatic) 10.6 (s, 1H, NCN proton); ¹³C{¹H}, δ 17.8 (s, o-methyls of mesityl), 21.2 (s p-methyl of mesityl), 29.8 (d, ${}^{1}J_{PC} = 15.99$ Hz, Ph₂PCH₂CH₂-N), 48.15 (d, $^{2}J_{PC} = 21.89$ Hz, Ph₂PCH₂CH₂-imidazole), 123 (s, imidazole backbone), 123.5 (s, imidazole backbone), 129 (d, $J_{PC} = 6.80$ Hz, aromatic), 129.15 (d, $J_{PC} = 8.31$ Hz, aromatic), 129.9 (s, aromatic), 130.8 (s, aromatic), 132.9 (d, $J_{\rm PC}$ = 18.87 Hz, aromatic), 134.4 (s, aromatic), 136.3 (d, $J_{\rm PC}$ = 11.32 Hz, aromatic), 138.5 (s, ipso to the imidazole), 141.3 (s, NCN); ³¹P{¹H}, δ –22.4 (s, Ph₂P(CH₂)₂–imidazole). Anal. Found: C, 63.57; H, 5.69; N, 5.31. Calcd for C₅₂H₅₆BrClN₄P₂·CH₂Cl₂ (1:1 bromide/chloride salt): C, 63.70; H, 5.85; N, 5.61

3-Mesityl-1-(y-(diphenylphosphino)-n-propyl)imidazolium Bromide (2c). This compound was prepared by following a method analogous to that for 2a from 4.5 g (8.8 mmol) of the oxide. Yield: 3.30 g (75%). NMR (CDCl₃): 1 H, δ 2.0 (s, 6H, o-methyls of mesityl), 2.1-2.3 (m, 4H, Ph₂P(O)CH₂(CH₂)₂imidazole and Ph₂P(O)CH₂CH₂CH₂-imidazole), 2.4 (s, 3H, p-methyl of mesityl), 5 (t, 2H, Ph₂P(O)(CH₂)₂CH₂-imidazole), 6.9 (s br, 2H, aromatics of mesityl), 7.1 (s br, 2H, imidazole backbone), 7.4–7.7 (m, 10H, aromatics of phosphine), 10.9 (s, 1H, NCN proton); $^{13}C\{^1H\},$ δ 17.8 (s, o-methyls of mesityl), 21.2 (s, *p*-methyls of mesityl), 24.4 (d, ${}^{1}J_{PC} = 10.56$ Hz, Ph₂P*C*H₂- CH_2CH_2 -imidazole), 27.1 (d, ${}^2J_{PC} = 18.09$ Hz, $Ph_2PCH_2CH_2$ -CH₂-imidazole), 50.6 (d, ${}^{3}J_{PC} = 19.06$ Hz, Ph₂PCH₂CH₂CH₂imidazole), 122.3 (s, imidazole backbone), 123.3 (s, imidazole backbone), 128.8 (d, $J_{PC} = 6.78$ Hz, aromatic), 129.1 (s, aromatic), 130 (s, aromatic), 130.8 (s, aromatic), 132.9 (d, J_{PC} = 19.22 Hz, aromatic), 134.3 (s, aromatic), 137.6 (d, J_{PC} = 12.44 Hz, aromatic), 139.1 (s, ipso to the imidazole moiety), 141.5 (s, N*C*N); ${}^{31}P{}^{1}H$, $\delta -16.6$ (s, Ph₂*P*(CH₂)₃-imidazole) Anal. Found: C, 68.66; H, 6.28; N, 6.39. Calcd for C₅₄H₆₀BrClN₄P₂ (1:1 bromide/chloride salt): C, 68.82; H, 6.42; N, 5.95.

Preparation of the Palladium Complexes. General Method. To a mixture of solid imidazolium salt (1 equiv) and KN(Si(CH₃)₃)₂ (1.1 equiv) was added precooled (-78 °C) THF with vigorous stirring. The solution of the free carbene generated in this way was added after 10 min via cannula to a solution of palladium precursor in THF at -78 °C. After the mixture was stirred at -78 °C for 10 min, it was allowed to reach room temperature and stirred for 2 h. Evaporation of the volatiles under reduced pressure, extraction of the solid residue into cold (0 °C) dichloromethane, filtration of the cold solution through Celite, concentration of the filtrates to 1-3mL, and addition of ether precipitated the product as a white to beige solid, which was collected by filtration and dried under vacuum.

[L^a]PdMe₂ (3a). This was prepared according to the general method using 0.11 g (0.44 mmol) of Pd(tmed)Me₂, 0.23 g (0.46 mmol) of L^aH, and 0.10 g of KN(SiMe₃)₂ (0.50 mmol). Yield: 0.18 g (70%). X-ray-quality crystals were grown by layering a THF solution with Et₂O. NMR (CD₂Cl₂): ¹H, δ –0.6 (d, ³ J_{PH} = 7.15 Hz, 3H, PdMe), -0.4 (d, ${}^{3}J_{PH}$ = 8.24 Hz, 3H, PdMe), 1.0 (d, ${}^{3}J_{\text{HH}} = 6.7$ Hz, 6H, CH(CH₃)₂), 1.1 (d, ${}^{3}J_{\text{HH}} = 6.7$ Hz, 6H, CH(CH₃)₂), 2.3 (m, 2H, (PPh₂CH₂CH₂-ylidene)PdMe₂), 2.7 (sept. ${}^{3}J_{HH} = 6.7$ Hz, 2H, CH(CH₃)₂), 4.3 and 4.4 (each br dt, 1H, (PPh₂CH₂CH₂-ylidene)PdMe₂), 6.8 (d, 1H, ylidene backbone), 7.0 (d, 1H, ylidene backbone), 7.1 and 7.2 (each s, 1H, aromatics), 7.3-7.4 (m, 7H, aromatics), 7.6-7.7 (m, 4H, aromatics); ${}^{13}C{}^{1}H{}(C_5D_5N)$, $\delta 0.05$ (d, ${}^{2}J_{PC} = 9.96$ Hz, Pd*C*H₃), 2.4 (d, ${}^{2}J_{PC} = 9.34$ Hz, PdCH₃), 24.4 (s, CH(CH₃)₂), 26 (s, CH(CH₃)₂), 29.7 (s, CH(CH₃)₂), 30.3 (d, (PPh₂CH₂CH₂-ylidene)-PdMe₂, ${}^{1}J_{C-P} = 14.61$ Hz), 49.35 (d, (PPh₂CH₂-ylidene)- $PdMe_2$, ${}^2J_{C-P} = 10.62$ Hz), 121 (s, imidazole backbone), 125.2 (s, aromatic), 125.4 (s, aromatic), 129.69 (d, $J_{PC} = 9.06$ Hz, aromatic), 130.34 (d, $J_{\rm PC}$ = 7.04 Hz, aromatic), 130.8 (s, aromatic), 134.74 (s, aromatic), 134.83 (d, $J_{\rm PC} = 5.03$ Hz, aromatic), 147.15 (ipso carbon of aryl), 187.77 (s, NCN). ${}^{31}P{}^{1}H{}$ (CD₂Cl₂), δ 12.45 (s, (PPh₂CH₂CH₂-ylidene)PdMe₂). MS (ES+): *m*/*z* 561 [(P-C)PdMe]⁺, 602 [M + MeCN]⁺. Mp: 154-156 °C dec. Anal. Found: C, 64.50; H, 6.77; N, 4.81. Calcd for C₃₁H₃₉N₂PPd: C, 64.52; H, 6.81; N, 4.85.

[L^b]PdMe₂ (3b). This was prepared according to the general synthetic method from 0.10 g (0.44 mmol) of Pd(tmed)Me₂, 0.24 g (0.45 mmol) of L^bH, and 0.09 g (0.46 mmol) of KN(SiMe₃)₂. Yield: 0.16 g (75%). NMR (CD₂Cl₂): ¹H, δ -0.6 (d, ³J_{P-H} = 7.68 Hz, 3H, PdCH₃), -0.5 (d, ${}^{3}J_{P-H} = 6.50$ Hz, 3H, PdCH₃), 2.0 (s, 6H, 2,6-methyls of mesityl), 2.1 (s br, 2H, (PPh₂CH₂-CH₂-ylidene)PdMe₂), 2.3 (s, 3H, 4-methyl of mesityl), 4.4 and (two sets of dt 1H each, (PPh₂CH₂CH₂-ylidene)PdMe₂), 6.7 (d, ${}^{3}J_{PH} = 7.68$ Hz, 1H, ylidene backbone), 6.9 (s. br., 2H, aromatics of mesityl), 7.0 (d, ${}^{3}J_{\rm PH}$ = 7.68 Hz, 1H, ylidene backbone), 7.4 (m, 5H, aromatics), 7.5–7.7 (m, 5H, aromatics); ¹³C{¹H} (C₅D₅N), δ 0.04 (d, ²*J*_{PC} = 9.87 Hz, Pd*C*H₃), 1.9 (d, ${}^{2}J_{PC} = 9.26$ Hz, Pd*C*H₃), 18.1 (s, *o*-methyls of mesityl), 22.2 (s, *p*-methyl of mesityl), 31.1 (d, ${}^{1}J_{PC} = 14.22$ Hz, (PPh₂*C*H₂CH₂ylidene)PdMe₂), 49.2 (d, ${}^{2}J_{PC} = 10.31$ Hz, (PPh₂CH₂CH₂ylidene)PdMe₂), 120 (s, imidazole backbone), 120.5 (s, imidazole backbone), 122.5 (s, aromatic), 123.8 (d, $J_{PC} = 8.05$ Hz, aromatic), 124.2 (s, aromatic), 124.7 (s, aromatic), 126.20 (d, $J_{\rm PC} = 9.06$ Hz, aromatic), 126.38 (d, $J_{\rm PC} = 5.03$ Hz, aromatic), 128.6 (s, aromatic), 148.5 (s, ipso carbon of the aryl), 185.8 (s, NCN); ${}^{31}P{}^{1}H$, δ 12.24 (s, (*P*Ph₂CH₂CH₂-ylidene)PdMe₂). MS (ES+): *m*/*z* 519 [L^bPdMe]⁺ (M), 560 [M + MeCN]⁺. Mp: 133-134 dec. Anal. Found: C, 57.33; H, 5.73; N, 4.49. Calcd for C28H34N2PPd·CH2Cl2: C, 56.10; H, 5.84; N, 4.51.

[L^a]PdBr₂ (4a). This compound was prepared by following the general method from 0.10 g of Pd(COD)Br₂ (0.27 mmol), 0.14 g (0.28 mmol) of LaH, and 0.06 g (0.30 mmol) of KN(SiMe₃)₂. Yield: 0.14 g (70%). NMR (CD₂Cl₂): ¹H, δ -0.4 (d, ${}^{3}J_{\text{HH}} = 6.8$ Hz, 6H, $CH(CH_{3})_{2}$), 1.3 (d, ${}^{3}J_{\text{HH}} = 6.8$ Hz, 6H, CH(CH₃)₂), 1.9 (m, 2H, (PPh₂CH₂-ylidene)PdBr₂), 2.1 (sept, ${}^{3}J_{HH} = 6.8$ Hz, 2H, CH(CH₃)₂), 4.3 and 4.4 (each dt, 1H, (PPh₂CH₂CH₂-ylidene)PdBr₂), 6.9 (s, 1H, ylidene backbone), 7.4-7.7 (m, 11H, aromatics), 7.7-7.8 (m, 3H, aromatics); ¹³C- $\{^{1}H\}, \delta 20.0 \text{ (s, CH}(CH_{3})_{2}), 23.5 \text{ CH}(CH_{3})_{2}), 26.2 \text{ (s, CH}(CH_{3})_{2}),$ 29.8 (s, (PPh₂CH₂CH₂-ylidene)PdBr₂), 48.0 (s, (PPh₂CH₂CH₂ylidene)PdBr₂), 122.2 (s, ylidene backbone), 124.6 (s, ylidene backbone), 127.1 (s, aromatic), 129.35 (d, $J_{PC} = 10.69$ Hz, aromatic), 130.3 (s, aromatic), 131.5 (s, aromatic), 132.13 (d, $J_{PC} = 2.92$ Hz, aromatic), 134.38 (d, $J_{PC} = 9.72$ Hz, aromatic), 136.8 (s, aromatic), 146.1 (s, ipso carbon of the aryl group), 160.8 (NCN); ${}^{31}P{}^{1}H$, δ 21 (s, (*P*Ph₂CH₂CH₂-ylidene)PdBr₂) Anal. Found: C, 50.88; H, 4.94; N, 3.55. Calcd for C₂₉H₃₄Br₂N₂-PPd·Et₂O: C, 50.69; H, 5.67; N, 3.58.

[L^b]PdBr₂ (4b). This was prepared by following the general method from 0.10 g (0.27 mmol) of Pd(COD)Br₂, 0.13 g (0.28 mmol) of L^bH and 0.06 g (0.30 mmol) of KN(SiMe₃)₂. Yield:

0.12 g (69%). X-ray-quality crystals were grown in an NMR tube by slow diffusion of Et₂O into a CH₂Cl₂ solution. NMR (CD₂Cl₂): ¹H, δ 0.9 (s, 6H, o-methyls), 1.3 (s, 3H, p-methyl), 1.8 (m, 2H, (PPh₂CH₂CH₂-ylidene)PdBr₂), 4.3 and 4.4 (each dt, 1H, (PPh₂CH₂CH₂-ylidene)PdBr₂), 6.8 (d, 1H, imidazolylidene backbone), 7.1 (s br, 1H, imidazolylidine backbone), 7.2 (s, 2H, mesityl aromatic protons), 7.2-7.7 (m, 10H, aromatics); $^{13}\text{C}\{^1\text{H}\},~\delta$ 17.9 (s, o-methyls of mesityl), 21.8 (s, p-methyl of mesityl), 30.1 (s, (PPh₂CH₂CH₂-ylidene)PdBr₂), 48.0 (s, (PPh₂CH₂CH₂-ylidene)PdBr₂), 121.0 (s, ylidene backbone), 124.4 (s, ylidene backbone), 127 (s, aromatic), 128.85 (d, $J_{PC} = 9.06$ Hz, aromatic), 130.3 (s, aromatic), 132.3 (s, aromatic), 133.5 (s, aromatic), 134.15 (d, $J_{PC} = 3.02$ Hz, aromatic), 135.03 (d, $J_{\rm PC}$ = 12.08 Hz, aromatic), 138.2 (s, aromatic), 147.1 (s, ipso carbon of the aryl group attached to the ylidene backbone), 162.4 (NCN); ${}^{31}P{}^{1}H$, δ 19 (s, (*PPh*₂-CH₂CH₂-ylidene)PdBr₂). Anal. Found: C, 44.24; H, 3.93; N, 3.85. Calcd for C₂₆H₂₈Br₂N₂PPd·CH₂Cl₂: C, 43.20; H, 4.03; N, 3.73.

Reaction of 3a with CH₃I. Formation of 5a. To a precooled (0 °C) solution of 0.08 g (0.14 mmol) of compound **3a** dissolved in 15 mL of dichloromethane was added via a microliter syringe a 3-fold excess of MeI (26 μ L, 0.42 mmol). The solution was brought to room temperature and was stirred overnight. A color change occurred within the first 30 min of stirring at room temperature, from pale yellow to deep orange. The solution was filtered through Celite, and the volatiles were removed under vacuum. Repeated recrystallizations from dichloromethane/ether at -35 °C gave orange crystals.

Preparation of the Salts 6a, 7a, 8a, and 9a. General Method. To a solution of **3a** in dichloromethane (20 mL) at -78 °C was added a solution of H(Et₂O){B[(3,5-CF₃)₂C₆H₂)]₄} (1 equiv in 20 mL of dichloromethane). The mixture was warmed to -40 to -50 °C when 1 equiv of pyridine, nitrile, or trimethylphosphine was added. After the mixture was warmed to room temperature, the volatiles were removed under reduced pressure and the residue was washed three times with ca. 10 mL of petroleum ether and dried under vacuum.

Preparation of $[L^aPd(CH_3)(C_5H_5N)]{B[(3,5-CF_3)_2-CF_3)_2-CF_3]}$ C_6H_2]₄ (6a). This was prepared by following the above general method from 3a (0.06 g, 0.1 mmol), H(Et₂O){B[(3,5- $(CF_3)_2C_6H_3)_4$ (0.09 g, 0.1 mmol), and pyridine (8 μ L, 0.1 mmol). Yield: 0.15 g, 96%. NMR (CD₂Cl₂): 1 H, δ -0.3 (d, ${}^{3}J_{PH} = 2.73$ Hz, 3H, PdCH₃), 0.8 (d, 6H, CH(CH₃)₂), 1.0 (d, 6H, CH(CH₃)₂), 2.5 (m, 4H, CH(CH₃)₂ and [Ph₂PCH₂CH₂-ylidene]PdMe(py)⁺), 4.3 and 4.4 (m, 1H each [Ph₂PCH₂CH₂-ylidene]PdMe(py)⁺), 6.9 (s, 1H, imidazole backbone), 7.0-7.2 (m, 4H, aromatic), 7.3-7.4 (d, 2H, aromatic), 7.5–7.9 (m, 25H, aromatic); $^{13}C\{^{1}H\},\,\delta$ 7.6 (s, PdCH₃), 23.3 (s, CH(CH₃)₂), 26.1 (s, CH(CH₃)₂), 29.1 (s, CH(CH₃)₂), 32.0 (s, [Ph₂PCH₂CH₂-ylidene]PdMe(py)⁺), 47.9 (s, $[Ph_2PCH_2CH_2-y]idene]PdMe(py)^+$; ³¹P{¹H}, δ 34.8 (s, $[Ph_2PCH_2-y]idene]PdMe(py)^+$; ³ CH₂-ylidene]PdMe(py)⁺); ¹⁹F, δ 100.2 (s, B[(3,5-CF_3)_2C_6H_3]_4⁻). Anal. Found: C, 51.77; H, 3.77; N, 2.49. Calcd for C₆₇H₅₄-BF₂₄N₃PPd·CH₂Cl₂: C, 51.36; H, 3.55; N, 2.64.

Preparation of [L^aPd(CH₃)(CH₃CN)]{B[(3,5-CF₃)₂- C_6H_2]₄ (7a). This was prepared by following the above general method from **3a** (0.06 g, 0.1 mmol), H(Et₂O){B[(3,5- $(CF_3)_2C_6H_2)]_4$ (0.09 g, 0.1 mmol), and CH_3CN (6 μ L, 0.11 mmol). Yield: 0.110 g, 75%. NMR (CD₂Cl₂, 300 MHz): ¹H, δ -0.1 (d, ${}^{3}J_{PH} = 1.83$ Hz, 3H, Pd*Me*), 1.1 (d, ${}^{3}J_{HH} = 6.37$ Hz, 6H, CH(CH₃)₂), 1.2 (dd, ${}^{3}J_{HH} = 6.37$ Hz, 6H, CH(CH₃)₂), 1.9 (s, 3H, MeCN), 2.6 (m, 4H, CH(CH₃)₂ and [Ph₂PCH₂CH₂ylidene]PdMe(NCMe)⁺), 4.1 and 4.2 (m, 1H each, [Ph₂PCH₂CH₂ylidene]PdMe(NCMe)+), 6.9 (s, 1H, ylidene backbone), 7.0 (s, 1H, ylidene backbone), 7.3 (d, 2H, aromatics), 7.4-7.6 (m, 8H, aromatic), 7.7–7.9 (m, 15H, aromatic). No ${}^{13}C{}^{1}H{}$ NMR data are available, due to sample decomposition during acquisition. Anal. Found: C, 49.76; H, 3.29; N, 4.26. Calcd for $C_{64}H_{52}BF_{24}N_3PPd \cdot CH_2Cl_2 \cdot 2CH_3CN$: C, 50.71; H, 3.70; N, 4.29.

Preparation of $[L^aPd(CH_3)(C_6H_5CN)]{B[(3,5-CF_3)_2-CF_3)_2-CF_3]}$ C_6H_2]₄ (8a). This was prepared by following the above general method from 3a (0.06 g, 0.1 mmol), H(Et₂O){B[(3,5- $(CF_3)_2C_6H_2)]_4\}$ (0.09 g, 0.1 mmol), and C_6H_5CN (10 μ L, 0.1 mmol). Yield: 0.14 g, 88%. NMR (CD₂Cl₂): ¹H, δ 0.0 (d, ³J_{PH} = 2.73 Hz, 3H, Pd*Me*), 1.1 (d, ${}^{3}J_{HH}$ = 7.29 Hz, 6H, CH(CH₃)₂), 1.3 (d, ${}^{3}J_{HH} = 6.38$ Hz, 6H, CH(CH₃)₂), 2.7 (m, 4H, CH(CH₃)₂) and [Ph₂PCH₂CH₂-ylidene]PdMe(NCPh)⁺), 4.1 and 4.2 (m, 1H each, [Ph₂PCH₂CH₂-ylidene]PdMe(NCPh)⁺), 6.9 (s, 1H, ylidene backbone), 7.1 (s, 1H, ylidene backbone), 7.2 (s, 4H, aromatic), 7.3 (broad s, 3H, aromatic), 7.4 (d, 2H, aromatic), 7.5-7.6 (m, 9H, aromatic), 7.7–7.9 (m, 12H, aromatic); ${}^{31}P{}^{1}H$, δ 36.5 [Ph₂PCH₂CH₂-ylidene]PdMe(NCPh)⁺); ¹⁹F, δ 100.2 (s, B[(3,5- $CF_{3}_{2}C_{6}H_{3}_{4}^{-}$). ¹³C{¹H}, δ 4.9 (s, PdCH₃), 24.4 (s, CH(CH₃)₂), 25.2 (s, CH(CH₃)₂), 29.3 (s, CH(CH₃)₂), 31.6 (d, ${}^{1}J_{PC} = 34.41$ Hz, [Ph₂PCH₂CH₂-ylidene]PdMe(NCPh)⁺)), 47.3 (s, [Ph₂PCH₂- CH_2 -ylidene]PdMe(NCPh)⁺), 117.5 (broad CF_3 's of BAr_4^{F-}), 118.2 (s, PhCN), 121.8 (s, ylidene backbone), 122.8 (s, ylidene backbone), 124.0 (s, aromatic), 124.2 (s, aromatic), 124.8 (s, aromatic), 126.7 (s, aromatic), 129.4 (s, aromatic), 129.9 (broad doublet J = 11 Hz, aromatic of BAr₄^F), 131.5 (s, aromatic), 132.6 (s, aromatic), 133.2 (s, aromatic), 134.16 (d, $J_{PC} = 11$ Hz, aromatic), 135.5 (s, aromatic), 136.3 (s, aromatic), 146.8 (s, ipso aromatic to the ylidene moiety), 161.7 (s, aromatic), 162.2 (s, aromatic), 162.7 (s, aromatic), 163.2 (s, NCN carbon); ³¹P{¹H}, δ 36.5 ([Ph₂*P*CH₂CH₂-ylidene]PdMe(NCPh)⁺), 36.3 (s, [Ph₂PCH₂CH₂-ylidene]PdMe(NCMe)⁺); ¹⁹F, δ 100.2 (s, B[(3,5- $CF_{3}_{2}C_{6}H_{3}_{4}^{-}$).

Preparation of [L^aPd(CH₃)(PMe₃)]{B[(3,5-CF₃)₂-C₆H₂)]₄} (9a). This was prepared by following the above general method from **3a** (0.058 mg, 0.1 mmol), H(Et₂O){B[(3,5-CF₃)₂C₆H₂)]₄} (0.094 mg, 0.1 mmol), and PMe₃ (8 μL, 0.11 mmol). Yield: 140 mg, 93.3%. NMR (CD₂Cl₂): ¹H, δ 0.0 (t, ³J_{PH} = 7.29 Hz, 3H, PdCH₃), 0.9 (m, 15H, PMe₃ and CH(CH₃)₂), 1.2 (d, ³J_{HH} = 7.29 Hz, 6H, CH(CH₃)₂), 2.4 (m, 2H, [Ph₂PCH₂-CH₂-ylidene]PdMe(PMe₃)⁺), 2.6 (sept, ³J_{HH} = 6.38 Hz), 4.3 and 4.4 (m, 1H each [Ph₂PCH₂CH₂-ylidene]PdMe(PMe₃)⁺), 7.0 (s, 1H, ylidene backbone), 7.15 (s, 1H, ylidene backbone), 7.2 (d, 2H, aromatic), 7.3-7.6 (m, 16H, aromatic), 7.7 (broad s., 7H, aromatic); ³¹P{¹H}, δ 4.6 (d, ²J_{PP} = 32.81 Hz, [Ph₂PCH₂CH₂ylidene]PdMe(PMe₃)⁺), -15.8 (d, ²J_{PP} = 32.81 Hz, [Ph₂PCH₂CH₂-CH₂-ylidene]PdMe(PMe₃)⁺); ¹⁹F, δ 100.2 (s, B[(3,5-CF₃)₂C₆H₃]₄⁻).

Preparation of 10a. To a cold solution of **4b** (60 mg, 0.085 mmol) in 20 mL of acetonitrile was added by cannela a solution of AgBF₄ (33 mg, 0.17 mmol in 5 mL of acetonitrile). Upon addition a gray precipitate was formed, which was filtered off through Celite while the mixture was kept at 0 °C. The resultant bright yellow solution was evaporated to dryness, and the yellow solid was characterized by NMR spectroscopy after dissolution in *d*₃-acetonitrile. NMR (CD₃CN): ¹H, δ 0.8 (d, 6H, CH(CH₃)₂), 0.9 (d, 6H, CH(CH₃)₂), 2.5 (2H, sept, C*H*(CH₃)₂), 2.8 (m, 2H, (PPh₂CH₂CH₂-ylidene)Pd(MeCN)₂²⁺), 4.4 and 4.6 (each dt, 1H, (PPh₂CH₂CH₂-ylidene)Pd(MeCN)₂²⁺), 7.1–8.0 (15H, aromatics and imidazole backbone); ³¹P{¹H}, δ 29.9 (s). The compound was unstable for further characterization.

Monitoring of the Reaction of 3a with $(CF_3)_2$ CHOH by NMR Spectroscopy. In the glovebox 20 mg of complex 3a was dissolved in C₅D₅N. The solution was then cooled to -78 °C, and 3-4 drops of hexafluoro-2-propanol using a microsyringe were added. The solution was brought to room temperature, and the NMR spectra were acquired. ¹H NMR (C₆D₅N, 400 MHz): δ 0.0 (d, ³J_{P-H} = 2.68 Hz, 3H, PdCH₃), 0.2 (CH₄), 0.9 (d, 6H, CH(CH₃)₂), 1.1 (d, 6H, CH(CH₃)₂), 2.6 (2H, sept, CH(CH₃)₂), 2.8 (m, 2H, (Ph₂PCH₂CH₂-ylidene)PdMe⁺), 4.4 and 4.6 (each dt, 1H, (Ph₂PCH₂CH₂-ylidene)PdMe⁺), 5.4 (sept, (CF₃)₂CHO⁻), 7.0–7.8 (m, 10H, aromatic and imidazolylidene backbone), 7.9–8.1 (m, 5H, aromatic). ¹³C NMR (C₆D₅N, 100.65 MHz): δ 7.98 and 8.03 (d, ²J_{P-C} = 4.6 Hz, PdCH₃), 23.7 (s, CH(CH₃)₂), 26.4 (s, CH(CH₃)₂), 29.4 (s, CH(CH₃)₂), 31.53 and 31.87 (d, ¹J_{P-C} = 34.2 Hz (PPh₂CH₂CH₂-ylidene)PdMe⁺), 47.7

Table 2. Crystallographic Data for Complexes 3a, 4b, 5a, 6a, and 7a

	3a	4b	5a	6a	7a
chem formula	C ₃₁ H ₃₉ N ₂ PPd	C ₂₆ H ₂₇ Br ₂ N ₂ PPd	C ₃₁ H ₃₈ Cl ₂ I ₃ N ₂ PPd	$C_{136}H_{105}B_2F_{48}N_6O_{0.50}P_2Pd_2$	C ₆₄ H ₅₁ BF ₂₄ N ₃ PPd
formula wt	577.01	664.69	999.64	3039.62	1466.26
cryst syst	monoclinic	triclinic	monoclinic	triclinic	triclinic
space group	$P2_1/n$	$P\bar{1}$	<i>I</i> 2/ <i>a</i> of <i>C</i> 2/ <i>cc</i>	$P\overline{1}$	$P\overline{1}$
a/Å	12.7219(5)	9.3880(2)	18.5870(4c	14.258(5)	10.2531(2)
b/Å	15.2549(8)	10.4022(2)	14.5626(3))	17.042(5)	15.1598(5)
c/Å	15.3658(6)	13.8831(3)	27.2787(6	27.324(5)	22.1848(7)
α/deg	90	69.2150(10)	90	92.213(5)	74.158(2)
β/deg	110.421(3)	88.9380(10)	108.7830(10)	94.633(5)	80.735(2)
γ/deg	90	77.9220(10)	90	91.630(5)	73.122(2)
V/Å ³	2794.7(2)	1237.17(4)	6990.4(3)	6610(3)	3161.89(16)
Ζ	4	2	4	2	2
<i>T</i> /K	150(2)	150(2)	120(2)	153(2)	120(2)
μ/mm^{-1}	0.743	4.062	2.596	0.417	0.433
no. of data collected	28 963	10 490	34 885	60 460	56 165
no. of unique data	6290	5607	7990	18 875	14 437
R _{int}	0.1825	0.0188	0.0484	0.1037	0.1028
final $R(F)$ for	0.0674	0.0283	0.0576	0.0669	0.0561
$F_{\rm o} > 2\sigma(F_{\rm o})$					
final $R(F^2)$ for all data	0.1051	0.0347	0.0877	0.1194	0.1117

(s, (PPh₂CH₂CH₂-ylidene)PdMe⁺), 71.7 (quintet, ${}^{1}J_{CF} = 31$ Hz, (CF₃)₂CHO⁻), 123.5 (s, ylidene backbone), 123.8 (s, ylidene backbone), 124.8 (s, aromatic), 125.5 (s, aromatic), 130.22 and 130.32, 131.4 (s, aromatic), 131.7 (s, aromatic), 132.6 (s, aromatic), 134.53 and 134.65, 146.6 (s, ipso aromatic carbon attached to the ylidene backbone), 180.3 (N*C*N carbon); ${}^{31}P{}^{1}H{}$ NMR (C₆D₅N, 121.44): δ 35.26 (s, (*P*Ph₂CH₂CH₂-ylidene)PdMe⁺).

Heck Catalytic Studies. A 1 mmol portion of aryl halide, 1.4 equiv of alkene (methyl acrylate unless otherwise stated), 2 equiv of base (NEt₃ or dried Cs₂CO₃), and 0.3 equiv of diethylene glycol-dibutyl ether (internal standard) were placed in a 50 mL Rotaflo ampule using a microliter syringe. A 1 mL portion of N-methyl-2-pyrrolidinone or N,N-dimethylacetamide was added to dissolve organics and 1 mL of solution of catalyst in the same solvent so that 0.5 or 0.01 mol % of catalyst/substrate was obtained. The ampule was then evacuated and placed in a preheated oil bath fitted with a thermostat. After the end of the catalytic run the ampule was cooled to room temperature and opened and the reaction mixture worked up by addition of water and dichloromethane, extraction, phase separation, drying and GC of the organic phases. GC yields (average of two runs) were calculated using diethylene glycol-dibutyl ether as an internal standard.

Copolymerization of CO and Ethylene. In a typical run 11 mg of complex **3a** was dissolved in 10 mL of dichloromethane, and the solution was transferred via cannula to a glass pressure reactor and cooled to -78 °C. To this solution was added 18 mg of Brookhart's acid dissolved in 10 mL of dichloromethane and cooled to -78 °C. After the addition was complete, the temperature was raised slowly to -30 °C and the apparatus was slowly pressurized with a 1:1 mixture of CO and ethylene up to about 20 psi. The slush bath was then removed, and the reaction mixture was pressurized to 5 bar. After 30 min the solution became cloudy. The reaction was quenched after 2 h with 30 mL of methanol. The precipitated polymer was filtered and dried under vacuum to yield 69 mg of poly(CO-*block*-ethylene). The polymer was dissolved in a 1:1

mixture of C₆D₆ and (CF₃)₂CHOH, and the NMR spectra were recorded. NMR (C₆D₆): δ 2.4 (s, poly(CO-*block*-(CH₂)₂), 3.2 (broad s, (CF₃)₂CHOH), 3.7 (sept, (CF₃)₂CHOH); ¹³C{¹H}, δ 35.9 (s, poly(CO-*block*-(CH₂)₂), 69.8 (sept. ²J_{FH} = 33.70 Hz, (CF₃)₂-CHOH), 122.5 (q, ¹J_{FH} = 281.80 Hz, (CF₃)₂CHOH), 212.3 (s, poly(CO-*block*-(CH₂)₂). IR: 2906 cm⁻¹ (CO stretching).

X-ray Crystallography. A summary of the crystal data and data collection and refinement details for compounds **3a**, **4b**, **5a**, **6a**, and **7a** are given in Table 2. All data sets were collected on a Enraf-Nonius Kappa CCD area detector diffractometer with an FR591 rotating anode and an Oxford Cryosystems low-temperature device operating in ω scanning mode with ψ and ω scans to fill the Ewald sphere. The programs used for control and integration were Collect, Scalepack, and Denzo.¹⁸ The crystals were mounted on a glass fiber with silicon grease, from Fomblin vacuum oil. All solutions and refinements were performed using the WinGX package¹⁹ and all software packages within. All non-hydrogen atoms were refined using anisotropic thermal parameters, and hydrogens were added using a riding model.

Acknowledgment. We thank Johnson Matthey Catalysts and the University of Southampton for financial support (to N.T.) and Prof. R. P. Tooze for initiating this collaborative research project and for helpful discussions.

Supporting Information Available: Full details of the X-ray crystal structures, including complete tables of crystal data, atomic coordinates, bond lengths and angles, and positional and anisotropic thermal parameters; these data are also available as CIF files. This material is available free of charge via the Internet at http://pubs.acs.org.

OM034061S

 ⁽¹⁸⁾ Hooft, R. COLLECT; Nonius BV, 1997–2000. Otwinowski, Z.;
 Minor, W. SCALEPACK, DENZO. *Methods Enzymol.* 1997, *276*, 307.
 (19) Farrugia, L. J. *J. Appl. Crystallogr.* 1999, *32*, 83.